Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Launches Lyrica Nine Months After First Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Pregabalin gestational period encompassed approval of three indications, DEA scheduling and production of packaging.
Advertisement

Related Content

FDA Controlled Substances Staff To Focus On Early Engagement With Sponsors
FDA Controlled Substances Staff To Focus On Early Engagement With Sponsors
Depomed Starts Gabapentin Extended Release Pivotal Trial
Depomed Starts Gabapentin Extended Release Pivotal Trial
Pfizer Sings Lyrica's Praises In Beating Earnings Guidance
Pfizer Sings Lyrica's Praises In Beating Earnings Guidance
Pfizer Guidelines Call For Physician Education For Six Months Prior To DTC
Lyrica Will Be Available In Fall, Pfizer Says
Lyrica Will Be Available In Fall, Pfizer Says
Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows

Topics

Advertisement
UsernamePublicRestriction

Register

PS062923

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel